611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
'Yo-Yo' Blood Pressure Numbers in Youth a Bad Sign for Health LaterFlame Retardants, Pesticides Remain Threat to U.S. Health: StudyDon't Want a 2nd Heart Attack? Lose the Belly FatHow to Keep Those Blood Vessels PumpingScreening for Chinese Coronavirus to Start at 3 Major Airports: CDCDo You Take Warfarin? Time of Day Might Not MatterHealth Tip: Signs of Food PoisoningSepsis Causes Far More Deaths Worldwide Than ThoughtMillennials Most Likely to Skip Flu Shot, Believe 'Anti-Vaxxer' Claims: PollResearchers Alter Mosquitoes to Resist Dengue InfectionMany Americans Are Inactive, With Southerners Faring WorseVirtual Reality Can Bring Real-Life PainAre Doctors Discarding 'Injured' Kidneys That Might Be Used for Transplant?Nerve Stimulation Therapy Could Cut Fibromyalgia PainWhich Obesity Surgery Is Right for You?Brake Dust Another Driver of Air PollutionWhat Works Best to Help Men With Overactive Bladder?More Studies Link Vaping to Asthma, COPDCertain Diabetes Meds May Lower Gout Risk, TooHeart Transplants From Donors With Hepatitis C May Be Safe: StudyClimate Change May Translate Into More Fatal InjuriesAll in the Timing: Many Get Knee Replacement Too Late or Too SoonHealth Tip: Preparing for an UltrasoundLow Levels of Key Blood Cells Could Signal Higher Death RiskGyms Are Fertile Ground for GermsTwo More Heartburn Meds Recalled Due to Possible CarcinogenZika Damage Showing Up in Babies Deemed 'Normal' at BirthHealth Tip: Coping With Winter NosebleedsHeart Disease May Up Risk of Kidney FailureFlu Cases Surge Early, Could a Tough Season Lie Ahead?Cluster of Unhealthy Risk Factors Could Raise Odds of Recurrent Blood ClotsAHA News: Worried About Dementia? Check This Blood Pressure NumberNew Study Reports Alarming Surge in E-Scooter AccidentsSo Long, 98.6: Average Human Body Temperature Is DroppingWhat Matters More for Obesity Risk, Genes or Lifestyle?Health Tip: Protect Yourself From Household ChemicalsOzone, Wood Smoke Raise Odds of COPD in Smokers and NonsmokersSmog May Be Bad for Your BonesEver Get a Rash from Your Skin Cream or Makeup? Here's WhyHealth Tip: 5 Eye Myths DebunkedHealth Tip: Allergic Reaction First AidTB Vaccine More Powerful When Given IntravenouslyGene Therapy May Be Long-Term Cure for Type of HemophiliaClots in Space: Astronaut's Blocked Vein Brings Medical InsightHealth Tip: Help Your Child Safely Lose WeightPatients Often Bring Undetected 'Superbug' to the Hospital: StudyExperimental Drug Could Be New Option Against ArthritisBanned for Decades, DDT and Dioxins Are Still Harming U.S. BabiesHealth Tip: When Bruising is a Red FlagAmericans Need to Tackle Youth Obesity: U.S. Task Force
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

FDA Approves Oxbryta for Treatment of Sickle Cell Disease


HealthDay News
Updated: Nov 26th 2019

new article illustration

TUESDAY, Nov. 26, 2019 (HealthDay News) -- Oxbryta (voxelotor) has been granted accelerated approval for the treatment of sickle cell disease in patients ages 12 years and older, the U.S. Food and Drug Administration announced Monday.

Oxbryta is the first approved treatment for sickle cell disease that directly inhibits the root cause of the disease, sickle hemoglobin polymerization, according to a company press release. Nonclinical studies of Oxbryta have shown the drug inhibits red blood cell sickling and improves red blood cell deformability and the ability of blood to flow. The recommended dosage of Oxbryta is 1,500 mg orally once daily with or without food. For severe hepatic impairment, the recommended dosage is 1,000 mg orally once daily.

Approval of Oxbryta was based on clinical data from the HOPE Study of 274 patients with sickle cell disease who received 1,500 or 900 mg of Oxbryta (90 and 92 patients, respectively) or placebo (92 patients). After 24 weeks of treatment, 51.1 percent of patients who received 1,500 mg of Oxbryta achieved an increase of greater than 1 g/dL in hemoglobin response rate compared with 6.5 percent of patients who received placebo.

Commonly reported side effects with Oxbryta include headache, diarrhea, abdominal pain, nausea, fatigue, rash, and fever.

Approval was granted to Global Blood Therapeutics. The drug is expected to be available through a specialty pharmacy partner network within two weeks.

More Information